ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) announced the presentation today of recently updated overall survival (OS) results and immune response data from the phase 2 …
Although ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) does not have any approved drugs, Roth Capital remains bullish on its pipeline and impending Phase III trials …
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) announced it has entered into a sponsored research agreement with Dr. Cassian Yee at the University of Texas MD …
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) announced financial results for the third quarter 2015. Andrew Gengos, ImmunoCellular Chief Executive Officer, commented: “With the many milestones …
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) announced that its Board of Directors has appointed Mark A. Schlossberg and Gregg A.
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) issued the following letter to shareholders. To Our Shareholders: As we work toward building a leading cancer immunotherapy company, …
In a research report released earlier today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on shares of ImmunoCellular Therapeutics (NYSEMKT:IMUC) with …
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) announced that it has reached agreement with the US Food and Drug Administration (FDA) on a Special Protocol Assessment …
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) announced the establishment of an agreement with Novella Clinical (Novella), to conduct the phase 3 registration trial of ICT-107 in …
ImmunoCellular Therapeutics Ltd (NYSE MKT:IMUC) announced an agreement with Pure MHC, an Emergent Technologies portfolio company, for development of a novel assay for quality …
